Heterocyclic compounds for cancer imaging and treatment and methods for their use
US11345670B2 · kind B2 · utility
5Cited by
29References
31Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | May 1, 2020 |
| Grant date | May 31, 2022 |
| Priority date | — |
| Expiry date | May 1, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D295/088
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, X, n1, n2, and n3 are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.